Clinical update: Treatment of glioblastoma multiforme with radiolabeled antibodies that target tumor necrosis

Current Cancer Therapy Reviews

Volumn 6, Issue 1, 2010, Pages 13-18

  Jensen, Randy L ^a   Shan, Joseph S ^b   Freimark, Bruce D ^b   Harris, Debra A ^b   King, Steven W ^b   Lai, Jennifer ^b   Parseghian, Missag H ^b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b Peregrine Pharmaceuticals Inc   (United States)

Author keywords

Clinical trial; Convection enhanced delivery; Glioblastoma multiforme; Local delivery; Malignant glioma; Radioimmunotherapy

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CHIMERIC ANTIBODY; COTARA; IBRITUMOMAB TIUXETAN; IODINE 131; IRINOTECAN; LOMUSTINE; MONOCLONAL ANTIBODY; PLACEBO; PROCARBAZINE; RECOMBINANT INTERLEUKIN 13; TEMOZOLOMIDE; TENASCIN ANTIBODY I 131; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE;

APHASIA; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BRAIN EDEMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONVULSION; CRANIOTOMY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; GLIOBLASTOMA; GLIOSARCOMA; HEMIPARESIS; HUMAN; ISOTOPE LABELING; LUNG CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RECURRENT CANCER; REVIEW; SURVIVAL TIME; THERMODYNAMICS; TUMOR GROWTH; TUMOR NECROSIS; UTERINE CERVIX CARCINOMA; VOMITING;

EID: 77949888505     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339410790596489     Document Type: Review

References (40)

1. CBTRUS. Statistical report: Primary brain tumors in the United States, 2000-2004. pp. 1-55.
2. Also, Statistical Report Supplement for 2004. pp. 1-42. 2008. Hinsdale, IL, Central Brain Tumor Registry of the United States.
3. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-25.
4. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006; 11: 152-64.
5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
6. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
7. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol 2003; 5: 79-88.
8. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-9.
9. Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunotherapy with murine Iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006; 24: 115-22.
10. Vose JM. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 2004; 9: 160-72.
11. Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med 2004; 34(Suppl 1): 4-9.
12. Cooper EH. The biology of cell death in tumors. Cell Tissue Kinet 1973; 6: 87-95.
13. Cooper EH, Bedford A, Kenny T. Cell death in normal and malignant tissues. Adv Cancer Res 1975; 21: 51-120.
14. Epstein AL, Chen F-M, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988; 48: 5842-8.
15. 131I-labeled TNT-1 monoclonal antibody. Cancer Res 1989; 49: 4578-85.
16. Chen FM, Epstein AL, Li Z, Taylor CR. A comparative autoradiographic study demonstrating differential intratumor localization of monoclonal antibodies to cell surface (Lym-1) and intracellular (TNT-1) antigens. J Nucl Med 1990; 31: 1059-66.
17. Van Walleghen DM, Parseghian MH. Toxicity and biodistribution of an iodine-131-radiolabelled tumour necrosis-targeting antibody in non-tumour bearing domestic felines. Vet Comp Oncol 2006; 4: 9-20.
18. Parseghian MH, Hamkalo BA. A compendium of the histone H1 family of somatic subtypes: an elusive cast of characters and their characteristics. Biochem Cell Biol 2001; 79: 289-304.
19. Chen S, Yu L, Jiang C, et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol 2005; 23: 1538-47.
20. Patel SJ, Shapiro WR, Laske DW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 2005; 56: 1243-52.
21. Shapiro WR, Carpenter SP, Roberts K, Shan JS. (131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin Biol Ther 2006; 6: 539-45.
22. Street HH, Goris ML, Fisher GA, et al. Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother Radiopharm 2006; 21: 243-56.
23. Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm 2002; 17: 359-70.
24. Epstein AL, Khawli LA, Hornick JL, Taylor CR. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. Cancer Res 1995; 55: 2673-80.
25. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm 2006; 21: 5-14.
26. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91: 2076-80.
27. Hoffman WF, Levin VA, Wilson CB. Evaluation of malignant glioma patients during the post-irradiation period. J Neurosurg 1979; 50: 624-9.
28. De Witt MC, de Bruin HG, Ejkenboorn W, Smikttt Sillevis AE, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004; 63: 535-7.
29. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007; 82: 81-3.
30. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26: 2192-7.
31. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9: 453-41.
32. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008; 113: 405-10.
33. Parney IF, Kunwar S, McDermott M, et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 2005; 102: 267-75.
34. Chamberlain MC. Pseudoprogression in glioblastoma. J Clin Oncol 2008; 26: 4359-60.
35. Chandler KL, Prados MD, Malec M, Wilson CB. Long-term survival in patients with glioblastoma multiforme. Neurosurgery 1993; 32: 716-20.
36. Scott JN, Rewcastle NB, Brasher PM, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999; 46: 183-8.
37. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain 2007; 130(Pt 10): 2596-606.
38. Kraus JA, Wenghoefer M, Schmidt MC, et al. Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J Neurol 2000; 247: 455-60.
39. McLendon RE, Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 2003; 98: 1745-8.
40. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001; 12: 259-66.